PDCD1 and head and neck squamous cell carcinoma: Another drug that inhibits the binding of PD-L1 to both PD-1 and CD80 is Nivolumab, IgG4 monoclonal antibody; it is also approved by the FDA for the treatment of R/M-HNSCC [12].